相似文献
1
Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.
Vaccine. 2010 May 21;28(23):3963-71. doi: 10.1016/j.vaccine.2010.03.046. Epub 2010 Apr 9.
2
Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
J Virol. 2005 Nov;79(21):13338-49. doi: 10.1128/JVI.79.21.13338-13349.2005.
3
Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
PLoS One. 2013 Oct 1;8(10):e78521. doi: 10.1371/journal.pone.0078521. eCollection 2013.
4
Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
Front Immunol. 2020 Jun 2;11:984. doi: 10.3389/fimmu.2020.00984. eCollection 2020.
5
Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.
Vaccine. 2008 Sep 19;26(40):5083-94. doi: 10.1016/j.vaccine.2008.03.092. Epub 2008 Apr 24.
6
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
Virology. 2007 Mar 30;360(1):218-34. doi: 10.1016/j.virol.2006.10.017. Epub 2006 Nov 13.
7
Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.
Vaccine. 2011 Aug 5;29(34):5611-22. doi: 10.1016/j.vaccine.2011.06.017. Epub 2011 Jul 14.
8
[Immunogenicity of plasmid DNA and adenoviral vectors encoding HIV-1 subtype B env gene].
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010 Dec;24(6):415-7.
9
Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity.
Front Immunol. 2024 Sep 24;15:1476924. doi: 10.3389/fimmu.2024.1476924. eCollection 2024.
10
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
PLoS One. 2013 Dec 3;8(12):e82380. doi: 10.1371/journal.pone.0082380. eCollection 2013.
引用本文的文献
1
The use of adenoviral vectors in gene therapy and vaccine approaches.
Genet Mol Biol. 2022 Oct 7;45(3 Suppl 1):e20220079. doi: 10.1590/1678-4685-GMB-2022-0079. eCollection 2022.
2
Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.
PLoS One. 2013 Oct 15;8(10):e76344. doi: 10.1371/journal.pone.0076344. eCollection 2013.
3
Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.
J Virol. 2013 Apr;87(7):3668-77. doi: 10.1128/JVI.02864-12. Epub 2013 Jan 9.
4
Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.
Clin Vaccine Immunol. 2012 May;19(5):629-37. doi: 10.1128/CVI.00010-12. Epub 2012 Mar 21.
5
MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes.
Vaccine. 2011 Jun 15;29(27):4476-84. doi: 10.1016/j.vaccine.2011.04.044. Epub 2011 May 5.
本文引用的文献
1
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.
J Immunol. 2009 Mar 15;182(6):3718-27. doi: 10.4049/jimmunol.0803115.
2
Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.
J Virol. 2009 Jan;83(2):791-801. doi: 10.1128/JVI.01672-08. Epub 2008 Oct 29.
3
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.
Virology. 2008 Dec 20;382(2):217-25. doi: 10.1016/j.virol.2008.09.016. Epub 2008 Oct 22.
4
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.
Expert Opin Biol Ther. 2008 Sep;8(9):1347-63. doi: 10.1517/14712598.8.9.1347.
5
Estimation of HIV incidence in the United States.
JAMA. 2008 Aug 6;300(5):520-9. doi: 10.1001/jama.300.5.520.
6
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7. doi: 10.1073/pnas.0802203105. Epub 2008 May 19.
7
Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.
Virology. 2008 May 10;374(2):322-37. doi: 10.1016/j.virol.2007.12.037. Epub 2008 Feb 5.
8
Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.
Virology. 2008 Mar 15;372(2):273-90. doi: 10.1016/j.virol.2007.10.022. Epub 2007 Dec 3.
9
Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.
J Virol. 2007 May;81(10):5024-35. doi: 10.1128/JVI.02444-06. Epub 2007 Feb 28.
10
A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
J Virol. 2007 Apr;81(7):3414-27. doi: 10.1128/JVI.02453-06. Epub 2007 Jan 17.
Zotero 插件